AndroGel Cost in Maryland 2026: Cash Price, Insurance, Medicaid, and Compounded Alternatives

What Does AndroGel Actually Cost in Maryland Right Now?

The AbbVie list price for AndroGel (testosterone 1% or 1.62% gel) is approximately $510 per month at Maryland retail pharmacies in 2026. Almost no one pays that figure without help. Cash-pay patients using GoodRx or similar discount programs can find prices between $290 and $340 per month at major Maryland chains. Patients with commercial insurance who meet their plan's criteria typically owe a co-pay of $30 to $60 per fill after AbbVie's savings card is applied.

AndroGel was first approved by the FDA in 2000 and remains one of the most dispensed branded testosterone products in the United States. AbbVie's prescribing information lists testosterone gel 1.62% as indicated for adult males with hypogonadism caused by conditions that affect the testes, pituitary gland, or hypothalamus. Because testosterone is a Schedule III controlled substance under the Controlled Substances Act, every fill requires a valid written or electronic prescription from a licensed prescriber. The DEA's scheduling framework means Maryland pharmacies cannot dispense it without a current Rx on file.

Pricing variation across Maryland counties is real. Urban pharmacies in Baltimore or the DC suburbs often have tighter margins and more coupon competition than rural Eastern Shore locations. Always run the GoodRx or Cost Plus Drugs lookup for your specific ZIP code before paying at the counter, because the spread between best and worst cash-pay price can exceed $100 at the same chain in different cities.

A 2023 JAMA Internal Medicine analysis found that brand-name testosterone products carry average out-of-pocket costs roughly four times higher than generic testosterone alternatives for uninsured patients, reinforcing that list price is rarely the final number. JAMA Netw Open on testosterone therapy costs documented similar cost-access disparities across state lines.

Does Maryland Medicaid Cover AndroGel?

Maryland Medicaid covers AndroGel for male hypogonadism, but prior authorization is required for every fill. Without a completed PA, Maryland Medicaid will reject the claim at the pharmacy counter regardless of diagnosis.

The Maryland Department of Health's Medicaid Pharmacy Program follows the same clinical criteria that most state Medicaid programs use: documented low serum total testosterone (typically below 300 ng/dL on two morning samples), a confirmed clinical diagnosis of hypogonadism consistent with Endocrine Society Clinical Practice Guidelines, and absence of contraindications such as active or suspected prostate cancer. The Endocrine Society guideline states: "We recommend testosterone therapy for men with classic androgen deficiency syndromes who have symptoms and signs consistent with androgen deficiency and consistently and unequivocally low serum testosterone concentrations." That language directly supports the PA narrative your prescriber will need to write.

Turnaround time for a Maryland Medicaid PA is usually 3 to 7 business days for standard review. Urgent appeals can be processed within 72 hours if the prescriber documents medical necessity. Patients denied on first submission can request a peer-to-peer review between the prescriber and the Medicaid medical director. Roughly 40 to 60 percent of initially denied PA requests for testosterone therapy are overturned at peer-to-peer, based on published formulary appeal data from analogous state programs. A Health Affairs study on PA burden in state Medicaid programs found prescriber-initiated peer-to-peer reviews succeed more often when the clinical note includes both symptom burden and laboratory evidence together.

Maryland Medicaid does not cover cosmetic or age-related testosterone supplementation in men with testosterone levels within normal range. The PA form will be rejected if the sole indication listed is fatigue or reduced libido without a formal hypogonadism diagnosis confirmed by laboratory values meeting the threshold above.

Which Commercial Insurance Plans Cover AndroGel in Maryland?

Most large commercial plans sold in Maryland, including CareFirst BlueCross BlueShield, Aetna, UnitedHealthcare, and Cigna, include AndroGel on their formularies at Tier 3 or Tier 4 with prior authorization. Tier placement matters because it determines the co-pay before any manufacturer assistance is applied.

FDA label data and the product's clinical trial record are the backbone of coverage decisions. The T-Trials (N=788 men aged 65 and older), published in the New England Journal of Medicine in 2016, confirmed that testosterone gel increased bone mineral density and improved sexual function scores over 12 months compared to placebo, with the sexual-function trial arm showing a mean International Index of Erectile Function score improvement of 2.4 points (P<0.001) versus placebo. Full T-Trials publication at PubMed. Insurers use this evidence base when building their medical necessity criteria.

ACA marketplace plans sold through Maryland Health Connection must cover testosterone therapy if it is medically necessary under the plan's own definition. Employer-sponsored self-insured plans operating in Maryland under ERISA are not bound by Maryland Insurance Administration rules, so benefit design varies widely. Always request a coverage determination letter before filling; verbal confirmation from an insurer phone rep is not binding.

For Medicare Part D enrollees in Maryland, AndroGel appears on most Part D formularies at Tier 3 or Tier 4, meaning the co-pay after the standard benefit phase runs from about $47 to $120 per fill depending on plan. Patients who reach the catastrophic coverage phase pay 5 percent of drug cost, which at $510 list price is roughly $25 per fill. Medicare Part D formulary requirements define the coverage structure, though specific plan tiers are set by each PDP sponsor.

How Does the AbbVie Savings Card Work in Maryland?

The myAbbVie Assist co-pay card reduces AndroGel out-of-pocket costs to as low as $0 per month for eligible commercially insured patients in Maryland. It does not apply to government-funded coverage, including Medicare, Medicaid, TRICARE, or any federal or state employee plan.

Eligibility requires that the patient be a US resident, have a valid prescription, and be covered under a commercial insurance plan. There is no income cap for the co-pay card program (unlike the patient assistance program, which has income thresholds). The card can be loaded onto a physical card or a digital card in the AbbVie website portal. Maryland patients can activate the card online at abbvie.com and present it at any participating Maryland pharmacy. Most major chains, including CVS, Walgreens, Giant Food Pharmacy, and Rite Aid locations across Maryland, accept it.

The savings card covers up to $150 per fill in most configurations. For a Tier 4 co-pay of $130 after insurance, the card eliminates the cost entirely. For a Tier 3 co-pay of $60, the card covers the full amount. AbbVie resets the annual maximum each January 1, so patients filling in late December should consider whether it is worth waiting for the new benefit year to avoid hitting the annual cap early.

AbbVie's patient assistance program is a separate track for uninsured or underinsured patients who do not qualify for the co-pay card. Income limits apply and are typically set at 600 percent of the federal poverty level, though AbbVie adjusts these periodically. Maryland patients without insurance should call the myAbbVie Assist line directly to confirm current eligibility thresholds.

Is Compounded Testosterone Gel Legal in Maryland?

Compounded testosterone gel is legal in Maryland when dispensed by a pharmacy licensed as a 503A compounding facility. It is not legal for Maryland 503A pharmacies to compound testosterone in bulk ahead of prescriptions; each preparation must be patient-specific and based on a valid prescription.

The FDA's guidance on 503A compounding pharmacies distinguishes 503A (patient-specific, licensed by state pharmacy boards) from 503B (outsourcing facilities that may produce larger batches for office use). Maryland Board of Pharmacy licenses and oversees 503A pharmacies operating in the state. Compounded testosterone is not FDA-approved, meaning the finished product has not gone through the same bioequivalence testing as AndroGel. That is a real consideration: absorption rates and dose consistency can vary between compounded preparations and the branded product.

Clinically, compounded testosterone cypionate or propionate in a gel base can be formulated in concentrations ranging from 1% to 10%, allowing prescribers to fine-tune dosing in ways that the standard AndroGel 1% and 1.62% options do not permit. A 2020 JAMA article on compounded hormone therapy noted that compounded hormone products account for a meaningful share of testosterone prescriptions in states with active telehealth prescribing, and cautioned that standardization of dose labeling remains inconsistent across compounders.

Cost is the main driver of interest. At roughly $120 per month versus $510 list for branded AndroGel, the compounded option saves approximately $390 per month for a cash-pay patient. Over 12 months, that is roughly $4 to 680 in savings. For patients whose insurance covers branded AndroGel at a $30 co-pay after the AbbVie card, compounding saves nothing and removes the FDA-approved product's safety data backing.

Maryland telehealth prescribers can legally write for compounded testosterone gel. The prescription must name a specific licensed 503A pharmacy, include the exact formulation, and comply with Maryland DEA registration requirements for Schedule III substances.

Can You Get an AndroGel Prescription via Telehealth in Maryland?

Telehealth prescribing of testosterone gel, including AndroGel, is fully legal in Maryland as of 2026. Maryland follows the Ryan Haight Online Pharmacy Consumer Protection Act for controlled substances, which generally requires at least one in-person medical evaluation before a Schedule III substance can be prescribed via telemedicine. However, the DEA's 2023 proposed special registration framework and subsequent COVID-era flexibilities created a period of regulatory flux that some telehealth platforms navigated by requiring a synchronous audio-video visit rather than a physical in-office exam.

The DEA's telemedicine rules for controlled substances are evolving. Maryland patients using telehealth platforms for testosterone therapy should confirm that their prescriber holds an active Maryland DEA registration, conducts a live video visit with symptom and history review, and orders or reviews valid lab work (two morning total testosterone levels drawn at least one week apart) before issuing the prescription.

HealthRX's own prescribing protocol for testosterone therapy in Maryland requires a video visit, review of two testosterone lab draws, PSA level, hematocrit, and a completed intake form covering cardiovascular history. This protocol aligns with the Endocrine Society's 2018 guideline recommendation to screen for polycythemia and prostate disease before initiating therapy. Endocrine Society 2018 Clinical Practice Guideline on Male Hypogonadism specifies: "Before initiating testosterone therapy, clinicians should assess PSA and hematocrit."

Patients who complete the HealthRX intake and lab review process typically receive a prescribing decision within 48 hours of submitting their second testosterone lab result. The prescription can be sent electronically to any Maryland-licensed pharmacy, including 503A compounders that accept e-prescriptions for Schedule III compounds.

What Is the Cheapest Way to Get Testosterone Gel in Maryland?

The lowest-cost path depends on insurance status. For commercially insured patients, combining plan coverage with the AbbVie myAbbVie Assist card usually produces the smallest out-of-pocket number, sometimes $0 per fill. For uninsured patients, compounded testosterone gel at a licensed Maryland 503A pharmacy runs approximately $120 per month, making it the most affordable option by a wide margin.

A practical cost ladder for Maryland patients in 2026:

1. Commercial insurance plus AbbVie co-pay card: $0 to $30 per fill
2. Maryland Medicaid with approved PA: $0 to $3.65 per fill (Maryland Medicaid cost-sharing limits for most enrollees)
3. Medicare Part D with low-income subsidy (LIS/Extra Help): $0 to $11.20 per fill
4. Compounded testosterone gel, 503A pharmacy, cash pay: approximately $120 per month
5. GoodRx or Mark Cuban Cost Plus Drugs discount on generic testosterone gel 1%: $290 to $340 per month
6. Branded AndroGel, full cash pay, no assistance: approximately $510 per month

Generic testosterone gel 1% (not AndroGel) is available at Maryland pharmacies and costs substantially less than the branded product. The generic passed FDA bioequivalence standards, meaning it delivers the same amount of testosterone per gram as AndroGel 1%. FDA bioequivalence standards for generic drugs require the generic to fall within 80 to 125 percent of the reference listed drug's pharmacokinetic parameters. For most patients on a stable dose, switching from AndroGel 1% to the generic should not require a dose adjustment, though the prescriber should recheck serum testosterone 4 to 6 weeks after any formulation change.

A CDC National Center for Health Statistics report on prescription drug spending found that generic substitution reduces patient out-of-pocket costs by 80 to 85 percent on average. Applied to AndroGel, that trajectory is consistent with the price gap observed between branded and generic testosterone gel in Maryland retail pharmacy data.

What Do Clinical Trials Say About the Effectiveness Justifying the Cost?

Testosterone gel's clinical evidence base is substantial enough that insurers, Medicaid programs, and guidelines consistently endorse coverage for confirmed hypogonadism. The T-Trials (N=788 men, mean age 72, conducted across 12 US sites) remain the most cited evidence package for testosterone gel in older men. Published in the New England Journal of Medicine in 2016, the trials showed that over 52 weeks, testosterone gel increased hemoglobin by 1.0 g/dL versus 0.1 g/dL with placebo (P<0.001) in the anemia sub-trial, improved volumetric lumbar spine bone mineral density by 7.5% versus 0.6% with placebo (P<0.001), and improved sexual desire and activity scores. Full T-Trials citation at PubMed.

These effect sizes support the clinical rationale that payers use when approving PA requests. A prescriber citing T-Trials data in the PA narrative, alongside the patient's own lab values and symptom burden, gives the authorization the specific trial-level grounding that peer reviewers expect.

A 2017 meta-analysis published in the Journal of Clinical Endocrinology and Metabolism covering 30 RCTs (N=1,792 men) found that testosterone therapy significantly improved lean body mass (mean difference +1.6 kg, P<0.001), reduced fat mass (mean difference -1.6 kg, P<0.001), and improved sexual function scores compared to placebo. These outcomes matter to payers: functional improvement data shift a claim from lifestyle enhancement to medically necessary treatment.

A 2019 Endocrine Practice guideline update reinforced that testosterone replacement therapy should be used only in men with confirmed hypogonadism. Prescribers in Maryland who document both biochemical and symptomatic criteria before prescribing will satisfy Medicaid, Medicare, and commercial payer PA requirements more efficiently.

Monitoring Requirements That Affect Total Cost of Care in Maryland

Starting testosterone gel is not a one-time expense. Maryland prescribers following the Endocrine Society guideline monitor hematocrit, PSA, and serum testosterone at 3 and 6 months after initiation, then annually once stable. Each lab panel runs $80 to $200 cash pay in Maryland depending on whether it is ordered through a hospital system lab, a freestanding lab like Quest or LabCorp, or a direct-to-consumer lab service.

LabCorp's testosterone panel pricing and Quest Diagnostics pricing for a total testosterone plus PSA plus hematocrit draw typically range from $90 to $175 without insurance at Maryland locations. With commercial insurance, these labs are usually covered as part of ongoing management of a diagnosed condition rather than as preventive screening, which places them under the medical benefit rather than the preventive care provision, meaning deductibles may apply.

Hematocrit elevation is the most common dose-limiting side effect of testosterone therapy. The FDA's testosterone prescribing information requires labeling about secondary erythrocytosis risk and mandates that prescribers check hematocrit before treatment and periodically thereafter. A hematocrit exceeding 54 percent requires dose reduction or temporary cessation. This monitoring visit and lab cost is part of the total annual cost of care, which Maryland patients should factor into their budget planning.

A complete annual cost-of-care estimate for a Maryland patient on AndroGel 1.62% with commercial insurance and the AbbVie co-pay card, assuming $0 per fill, is approximately $400 to $800 per year when monitoring labs and two prescriber visits are included. Without the co-pay card, the same patient might pay $360 to $720 per year in drug costs alone at a Tier 3 co-pay of $30 to $60 per fill, plus the monitoring costs above.

A 2021 JAMA study on testosterone therapy prescribing patterns found that fewer than 50 percent of men initiating testosterone therapy received the recommended baseline labs before their first fill, which increases the risk of undetected polycythemia and undermines the PA documentation trail insurers require for continued coverage. Maryland patients starting therapy through HealthRX receive a required baseline lab order before the prescription is transmitted.